Trump's US Pharmaceutical Pricing Ultimatum and the Evolving Drug Value Assessment Landscape

Trump's Ultimatum Demands Radical Price Cuts by September 29

On July 31, 2025, President Trump escalated his campaign against high U.S. drug prices by issuing ultimatum letters to 17 major pharmaceutical companies, demanding they implement "most favored nation" (MFN) pricing within 60 days or face government intervention. This unprecedented move intersects with a rapidly evolving U.S. healthcare landscape where value-based pricing, Health Technology Assessment (HTA), and drug price negotiations are fundamentally reshaping how pharmaceuticals are priced and reimbursed. The September 29, 2025 deadline represents both an immediate crisis and a long-term inflection point for the industry.

The ultimatum letters, posted publicly on Trump's Truth Social account and even read aloud at a White House press briefing, contain four specific demands that would fundamentally restructure U.S. pharmaceutical pricing.

Demand 1: Existing Portfolio MFN Pricing

Pharmaceutical companies must provide their full portfolio of existing drugs at MFN prices to all Medicaid patients – MFN pricing means matching the lowest price offered in any other developed nation.

Demand 2: Launch Price Guarantees

Drug manufacturers must guarantee that Medicare, Medicaid, and commercial payers receive MFN prices on all new drugs at launch, establishing international price parity from day one.

Demand 3: Revenue Reallocation Requirements

Pharmaceutical cmpanies must use the increased revenues from what Trump calls "foreign freeloading nations" (Trump's term for countries with lower drug prices) to directly lower U.S. prices through explicit agreements benefiting American patients and taxpayers.

Demand 4: Direct-to-Consumer Distribution

Pharmaceutical manufacturers must establish direct-to-consumer sales mechanisms, effectively bypassing pharmacy benefit managers (PBMs) and other intermediaries, to ensure all Americans can purchase medications at MFN prices.

The immediate market reaction was severe. The S&P 500 Pharmaceuticals Industry Index fell nearly 3% on July 31, and individual companies exposed to international price disparities saw even steeper drops. For example, shares of Sanofi plummeted by over 8%, while Bristol Myers Squibb and Novo Nordisk each fell about 5%, and Merck and GSK about 3%. Industry groups PhRMA and BIO sharply opposed the president’s price control demands, warning they would “undermine American leadership” in biopharmaceutical innovation. They instead pointed to supply-chain intermediaries as the real cost culprits, noting that pharmacy benefit managers and others “take nearly 50% of the costs of our medicines” via rebates and fees.

Market Impact Metrics

• S&P 500 Pharmaceuticals Index fell nearly 3% on July 31

• Sanofi shares plummeted over 8%

• Bristol Myers Squibb and Novo Nordisk each fell about 5%

• Merck and GSK declined approximately 3%

Industry Response Spectrum

Despite the market reaction, some pharma executives showed openness to the concept of global price alignment. AstraZeneca's CEO Pascal Soriot, for instance, agreed that drug pricing needs to "equalize" across countries. "The United States cannot build or carry the cost of R&D for the entire world," Soriot said, endorsing the idea that drug prices need to rise elsewhere and contribute more to research and development costs. Novartis likewise indicated it was exploring ways to meet the administration's MFN goals, with CEO Vas Narasimhan describing "productive, very open dialogue" with U.S. officials on solutions to equalize or lower U.S. prices, even if a final resolution would "take time".

Healthcare policy experts note, however, that Trump's authority to unilaterally enforce MFN pricing is highly limited. "The president, however, does not have the legal authority nor the regulatory tools to require drugmakers to sell their products at 'Most Favored Nation' prices in any market," said Spencer Perlman, director of health policy research at Veda Partners. Trump can pressure companies and direct federal agencies to test pricing models, but outright mandates would almost certainly face legal challenges. Indeed, Trump's similar MFN initiative in his first term – an attempt to base Medicare Part B payments on an international price index – was blocked by multiple federal courts and ultimately rescinded by the Biden administration in 2021.

The Fragmented U.S. HTA System Creates Unique Challenges

Unlike most developed countries, the United States lacks a single national HTA program. Instead, it operates through a complex, decentralized landscape of public and private HTA processes.

Current U.S. HTA Landscape Components

Private Insurer Assessments

Each private and commercial insurer conducts it's own internal health technology assessment (HTA) to decide whether and under what conditions to cover new therapies. through Pharmacy and Therapeutics (P&T) committees. These assessments determine formulary placement, prior authorization requirements, and coverage restrictions. Evidence standards vary significantly across insurers.

These processes often occur behind closed doors with varying evidence standards, leading to duplication of effort and inconsistent decisions.

Public Payer Programs

Medicare, Medicaid, the Veterans Administration (VA), and Department of Defense (DoD) each maintain separate evaluation processes. The Centers for Medicare & Medicaid Services (CMS), now performs HTA-like functions for Medicare through the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022.

The absence of a unified framework reflects the U.S. preference for market-oriented solutions, but it also creates significant inefficiencies and a lack of transparency in how value is determined.

ICER's Advisory Role

Amid this patchwork, the Institute for Clinical and Economic Review (ICER) has emerged as the closest thing to an independent national HTA body. ICER conducts rigorous evaluations of drugs' clinical effectiveness and cost-effectiveness, often using quality-adjusted life year (QALY) thresholds similar to England's NICE (typically in the range of $100,000–$150,000 per QALY). However, unlike NICE – whose guidance is binding for Britain's National Health Service – ICER's recommendations are advisory only and carry no direct authority to set U.S. prices or coverage. Despite this, ICER has gained considerable influence. Its well-publicized reports and value-based price benchmarks inform negotiations between drugmakers and payers, and have fueled public debate over what constitutes a "fair" price.

Federal Government's HTA Functions

The Inflation Reduction Act fundamentally altered CMS's role in value assessment, allowing the federal government to edge into HTA-like roles. Under the new Medicare Drug Price Negotiation Program, CMS is directed to consider each drug's therapeutic benefits and comparative clinical effectiveness when negotiating prices for Medicare. In doing so, CMS analyzes clinical trial data and real-world evidence much as HTA agencies do, to determine if a drug offers enough incremental value to justify its cost.

What CMS Must Consider

• Each drug's research and development costs

• Manufacturing and production costs

• Existing market revenues and unit sales

• Patient status and remaining exclusivity periods

• Availability of therapeutic alternatives

• Clinical benefit relative to existing treatments

• Extent of unmet medical need addressed

This framework requires CMS to conduct comprehensive comparative effectiveness analyses similar to established HTA agencies globally.

The FDA, for its part, maintains its traditional mandate of assessing safety and efficacy for approvals, but it increasingly coordinates with CMS on coverage and evidence generation issues (for example, aligning requirements for post-market studies or “coverage with evidence development” programs for certain accelerated approvals). Meanwhile, virtually every large private payer now has its own HTA-like committee reviewing new drugs, and 85% of U.S. payers say they would welcome a national assessment body to provide consistent evidence standards.

Key Statistics on U.S. HTA Landscape

• 85% of U.S. payers say they would welcome a national assessment body

• ICER convenes 3 independent evidence appraisal committees

• ICER publishes approximately 8–10 major drug reviews per year

• Companies begin compiling evidence packages 24–30 months before launch

Industry Adaptation Requirements

For pharmaceutical companies, preparing for U.S. market access has become a daunting exercise in multi-front navigation. Manufacturers must produce comprehensive HTA dossiers that can satisfy not just one decision-maker, but many. A typical dossier includes: systematic literature reviews of clinical evidence, comparative effectiveness data versus current standards of care, cost-effectiveness models (often with QALYs as an outcome), budget impact analyses for payers, real-world usage and safety data, and even patient-reported outcomes to demonstrate quality of life improvements.

Companies often begin compiling these evidence packages 24–30 months before launch. Many start with a core global value dossier (sometimes modeled after the NICE submission templates) as a foundation, then adapt and expand it to meet the unique requirements of various U.S. stakeholders – from ICER to each major insurer’s formulary committee. This early and proactive planning is now considered essential; without it, a drug with excellent clinical trial results could still stumble in securing coverage or favorable pricing amid America’s fractured HTA environment.

Core Value Dossier Evidence Components

• Systematic literature reviews (SLRs) of all relevant clinical evidence

• Direct and indirect treatment comparisons (ITCs) versus standard of care

• Cost-effectiveness models incorporating QALY calculations

• Budget impact analyses for 3-5 year horizons

• Real-world evidence (RWE) from early access programs

• Patient-reported outcomes demonstrating quality of life improvements

Value-Based Pricing Transforms Pharmaceutical Economics

The concept of value-based pricing (VBP) – tying a drug's price to the value it delivers in health outcomes – fundamentally differs from traditional cost-plus or purely market-driven pricing models. In recent years, at least six innovative VBP models have gained traction in the U.S. and abroad:

Six Innovative Value-based Pricing (VBP) Models

• Financial risk–based agreements: The manufacturer refunds or discounts the drug's cost if certain expenditure thresholds or patient spending caps are exceeded.

• Health outcomes–based contracts: The price paid (or rebate amount) is tied to the drug achieving agreed clinical targets in real-world patients.

• "Mortgage" models for curative therapies: Instead of one-time exorbitant payments, insurers pay for ultra-expensive cures over time.

• Subscription models ("Netflix model"): A flat fee for unlimited use of a therapy for a population over a period.

• Indication-specific pricing: The same drug costs differently for different uses, reflecting varying value across indications.

• Volume-based agreements for preventive therapies: Lower prices in exchange for broader population usage.

Concrete Examples in Practice

AstraZeneca & Harvard Pilgrim (Outcomes-Based): AstraZeneca struck an outcomes-based agreement with Harvard Pilgrim for the heart drug Brilinta, where AstraZeneca would adjust pricing based on patients' hospital readmission rates for acute coronary syndromes. The logic: Brilinta is intended to reduce heart attack recurrence and related hospitalizations; if patients taking the drug still end up in the hospital at a higher-than-expected rate, AstraZeneca provides additional rebates.

Washington State Hepatitis C Initiative (Subscription Model): In 2019, Washington announced a "Netflix model" contract with AbbVie for hepatitis C drugs, aiming to eliminate HCV in the state by 2030. The state pays a fixed annual fee and in return can treat an unlimited number of Medicaid and prison inmates with AbbVie's antiviral Mavyret.

GSK's Trobalt in France (Outcomes Guarantee): In France, regulators approved GSK's epilepsy drug Trobalt under an innovative agreement: GSK would not be paid at all for the drug until a patient had been on therapy for 12 months, to ensure it was effective for the patient. Furthermore, if a patient stopped Trobalt within the first 4 months due to lack of efficacy or side effects, the French health system would receive a full refund for the drug's cost; if the patient stopped between 5 and 12 months, GSK would be paid only a prorated amount equivalent to the cost of existing alternative treatments. This essentially guaranteed that France only paid the premium price if the new drug delivered sustained benefit over standard therapy.

Impact of the Inflation Reduction Act

IRA Medicare Negotiation Results

• First round: Average price reduction of 22% per drug

• Negotiated discounts ranged from 38% to 79% off list prices

• Projected Medicare savings: $6 billion in 2026

• Beneficiary out-of-pocket savings: $1.5 billion

• Second round targets 15 additional drugs affecting 5.3 million enrollees

• Second round drugs account for $40.7 billion in Part D spending

Meanwhile, the U.S. Inflation Reduction Act (IRA) of 2022 has accelerated a broader shift toward value and affordability. The first round of Medicare drug price negotiations — for 10 high-cost Part D drugs whose new prices take effect in 2026 — yielded an average price reduction of about 22% per drug compared to current Medicare costs. In aggregate, these lower prices are projected to save Medicare roughly $6 billion in 2026, and beneficiaries an additional $1.5 billion in out-of-pocket costs. The negotiated discounts off each drug’s list price ranged from 38% up to 79%, indicating Medicare was able to secure substantial concessions, especially on drugs that had seen very high U.S. to international price gaps.

The second round of negotiations, for prices effective in 2027, will target 15 additional drugs — a list that CMS announced in January 2025 including blockbuster diabetes and obesity medications like Ozempic and Wegovy (semaglutides) among others. These 15 drugs were used by 5.3 million Medicare enrollees and accounted for $40.7 billion in Part D drug spending in the past year. Negotiations in 2025 will determine how much prices for this group will drop by 2027.

The criteria laid out for Medicare’s negotiation process explicitly incorporate multiple value factors — the statutory framework directs CMS to consider each drug’s R&D and manufacturing costs, its existing market revenues, patents and remaining exclusivity, the availability of therapeutic alternatives, and the clinical benefit and unmet need addressed by the drug. In short, even the U.S. government is now in the business of assessing a drug’s value and leveraging that assessment to set pricing, something that was anathema in the U.S. system just a few years ago.

Global Pricing Pressures Demand a New Approach

Trump's ultimatum may be the most headline-grabbing example of pricing pressure on pharma, but it is part of a broader global transformation in how drug prices are governed. The United States, traditionally a free-pricing market, is moving closer to the international norm of price regulation tied to value. The Inflation Reduction Act's negotiation provisions mark the first time Medicare can directly intervene in drug pricing – a dramatic policy shift that is rippling through industry expectations.

European Developments

Across the Atlantic, European countries are tightening their already stringent price controls and value assessments. A new EU-wide HTA Regulation took effect in 2025, creating a framework for Joint Clinical Assessments (JCAs) at the European level. Under this system, for certain new drugs (initially cancer treatments and advanced therapies), EU member states will collaboratively assess the clinical evidence, producing a single JCA report that all national HTA agencies use as a basis for their decisions.

Country-Specific Reforms

Germany's AMNOG reforms: Germany has introduced new cost-containment rules that further constrain launch prices. Notably, for new drugs rated as having no added benefit, the negotiated price can no longer exceed the price of the appropriate comparator therapy — in fact, it must be at least 10% lower than the price of that comparator if the comparator is patented. Germany also made price-volume agreements (PVAs) mandatory in many negotiations, and the free pricing period for new drugs has been shortened from one year to 6 months.

France's value-based pricing framework: France has long used a value-rating system (ASMR I–V) to determine pricing relative to comparators. Recent French reforms aim to accelerate access for innovative drugs through the new "Direct Access" program while maintaining strict conditions: a drug with no improvement (ASMR V) is expected to be priced no higher than (or often below) the cheapest comparator.

Other EU examples: Spain, Italy, and others are expanding use of managed entry agreements that tie reimbursement to real-world results or utilize price-volume arrangements. European payers are collaborating via groups like the BeNeLuxA and Valetta initiatives to do joint price negotiations or share HTA information, increasing their leverage against manufacturers.

In emerging markets, pricing sophistication is also increasing. For example, China’s National Volume-Based Procurement (VBP) program has dramatically driven down prices for generic and some branded drugs by pooling public hospital procurement and forcing manufacturers to bid in large tenders. In ten rounds of VBP since 2018, prices for hundreds of drugs have dropped by an average of over 50%, and in some cases by 80–90% after competitive bidding. While this mainly affects multisource drugs, China has also pursued price negotiations for novel drugs entering its National Reimbursement Drug List, often extracting substantial discounts in exchange for volume access to the huge Chinese market.

Emerging Market Pressures

China's Volume-Based Procurement Impact

• Average price drops of over 50% across hundreds of drugs

• Some drugs seeing 80–90% price reductions after competitive bidding

• 10 rounds of VBP completed since 2018

• Now pursuing price negotiations for novel drugs entering National Reimbursement Drug List

In sum, the pricing strategies that might have succeeded in 2020 are quickly becoming obsolete by 2025. Pharmaceutical manufacturers must now navigate complex global networks of price references, negotiations, and regulations. A high launch price in one country can trigger ripple effects — reference price cuts elsewhere, or exclusion from formulary in a cost-sensitive market — more rapidly than ever. Trade tensions add another layer: for instance, Trump’s threats of tariffs on drugs from countries he deems “freeloaders” is an unconventional lever, but illustrates that drug pricing is now entangled with trade policy. The only sustainable response for companies is to demonstrably prove the value of their medicines. As pricing pressures intensify globally, the ability to justify a drug’s price with robust evidence has become the decisive factor in achieving and maintaining market access.

HTA Preparedness: The Gateway to Market Access Success

In this new reality, Health Technology Assessment preparedness has emerged as the critical gatekeeper of pricing and reimbursement decisions. Around the world, HTA agencies — including NICE in the UK, CDA-AMC in Canada, IQWiG and the G-BA in Germany, France's HAS, Australia's PBAC, and ICER in the U.S. — rigorously evaluate whether a new drug's health benefits justify its cost. Their determinations often dictate whether a therapy receives full reimbursement, partial coverage (perhaps with restrictions or caps), or no coverage at all. With healthcare budgets under unprecedented strain post-pandemic, HTA bodies have raised the bar for evidence. They expect to see not just modest clinical trial results, but compelling proof of real-world patient benefit and cost-effectiveness.

The New EU Joint Clinical Assessment

The new EU Joint Clinical Assessment process exemplifies the higher bar for evidence. A single JCA dossier will need to meet the consolidated requirements of multiple countries' HTA agencies for clinical data quality. If a company fails to provide sufficiently robust and relevant evidence within tight timelines, it could delay access across many markets at once. (Notably, once a sponsor's marketing application to EMA is validated, companies may have as little as 90 days to compile and submit the JCA dossier for the EU HTA, a very short window that demands extreme efficiency and pre-planning.)

Comprehensive Evidence Requirements

Globally, manufacturers are finding that HTA submissions must be more comprehensive than ever. Gone are the days of submitting a slim dossier with just one or two pivotal trials and some optimistic pharmacoeconomic modeling. Now, companies must anticipate and address a multitude of questions:

Key HTA Questions Companies Must Address

• How does the new drug compare to all relevant existing therapies on clinically meaningful endpoints?

• Does it meet an unmet need or improve quality of life?

• How durable are its benefits — do they translate into longer-term outcomes?

• What is the impact on healthcare budgets?

• Are there specific subpopulations who benefit more (or less)?

• What uncertainties remain, and how do they affect confidence in the cost-effectiveness?

Meeting these demands requires comprehensive clinical and economic evidence. This means robust clinical trials that measure patient-centric outcomes (not just surrogate endpoints), head-to-head trials or adjusted indirect comparisons to establish comparative efficacy, and long-term extension studies or real-world evidence to show durability and safety in practice. It also means high-quality health economic modeling – cost-utility analyses, budget impact forecasts – conducted according to the latest best practices, with transparency and sensitivity analyses. Increasingly, patient-reported outcomes and even societal benefits (e.g., productivity gains) are included to capture full value.

Beyond the Global Value Dossier

Crucially, dossier development is not a one-size-fits-all exercise. The most successful companies are moving beyond the static "global value dossier". They invest in deeply customized, dynamically updated submissions for each major HTA audience. For example, a company might prepare a core evidence dossier as a baseline, but then tailor the economic model with country-specific cost inputs and comparators, or emphasize certain endpoints more heavily depending on a given HTA agency’s preferences. They also scenario-plan extensively – essentially running virtual "what-if" HTA evaluations internally. By modeling different assumptions they can predict how the HTA outcome might change and preemptively address potential weaknesses. This level of preparation allows manufacturers to enter HTA discussions armed with answers and supplementary analyses, rather than reacting after the fact to negative assessments.

When done well, strong HTA preparedness yields a coherent value narrative that resonates with payers. The dossier connects all the evidence dots: it tells the story of how the new drug improves patient outcomes relative to existing options, at a cost that is justified by those improvements and perhaps offset by savings elsewhere, and how the uncertainty around these estimates has been considered and is outweighed by the potential benefits. Such dossiers have become essential for favourable reimbursement decisions in tight budget environments. Without them, even medically promising drugs can face delays, price reductions, or outright denial of coverage. On the flip side, a well-substantiated value proposition can persuade even skeptical payers that a therapy is worth investing in, despite cost pressures — especially if backed by real-world data from early use or innovative ri proposals that mitigate their financial risk.

Strong Value Evidence Drives Pricing Success

Experience in recent years has made one thing clear: companies that can demonstrate value with solid evidence achieve markedly better outcomes in pricing and market access. They secure higher negotiated prices and reimbursement rates, faster coverage decisions, more favorable formulary placements (e.g., fewer prior authorizations or step therapy requirements), and often smoother, shorter negotiations overall. Payers reward evidence – because credible data that a drug delivers significant health benefit gives them justification to pay for it, whereas weak evidence forces them to be conservative or demand steep discounts.

Hierarchy of HTA Evidence Influence

HTA Evidence Hierarchy

1. Robust RCTs with endpoints that matter for patients and payers (mortality, morbidity, quality of life)

2. Patient Groups Input lending humanistic weight to clinical and economic evidence

3. Indirect Treatment Comparisons demonstrating efficacy against relevant compparators

4. Long Term Extention Studies (LTE) demonstrating long-term efficacy and safety after trial has concluded

5. Health Economic Models showing cost-effectiveness below accepted thresholds

6. Real-World Evidence (RWE) demonstrating sustained benefits or unique advantages in routine care

7. Budget Impact Analyses projecting short-term (3-5 year) payer budget effects

Achieving this breadth of evidence requires early and strategic planning. Ideally, value planning starts by Phase II of development. Companies now commonly engage with payers or HTA agencies before pivotal trials are finalized – through scientific advice or consultation processes – to ensure their Phase III trials will measure outcomes that payers care about and include appropriate comparators.

Tiered Documentation Strategy

By Phase III, firms often assemble dedicated "market access teams" that develop the value story in parallel with clinical development. These teams prepare tiered documentation:

• A succinct payer value deck for quick discussions

• A comprehensive global value dossier with all detailed studies and models (often running hundreds of pages)

• Localized HTA submission dossiers adapted to each target country

• Objection handlers or clarifications– evidence-based rebuttals for anticipated payer concerns

The payoff for this rigorous approach is tangible. Companies that invest in comprehensive HTA dossiers and continuous evidence generation are commanding premium pricing in value-based agreements, even in notoriously stingy health systems. For instance, manufacturers who collected real-world outcomes after launch have been able to negotiate agreements that if the outcomes hold up, the price stays at a higher level. Those who failed to generate convincing evidence often face the opposite: increasing pressure to drop prices or risk exclusion.

Importantly, evidence generation no longer stops at approval – post-market data collection has become essential to demonstrate ongoing value. Some agreements require using electronic health records or claims data to track how patients fare on the drug; if the results disappoint, additional rebates kick in. Payers and manufacturers are even collaborating on setting up registries for this purpose. The most successful companies treat evidence generation and HTA engagement as an iterative, ongoing process throughout the product lifecycle, rather than a one-time hurdle at launch.

Strategic Imperatives for Market Access Executives

In this high-stakes environment, market access and HEOR (Health Economics and Outcomes Research) executives must fundamentally rethink their approach to HTA and pricing strategy. The convergence of Trump's immediate pricing pressure with the longer-term evolution of value frameworks has created a mandate for new levels of sophistication in evidence planning, dossier preparation, and predictive analytics.

Comprehensive Intelligence Gathering

Comprehensive intelligence gathering is non-negotiable. Every major HTA decision globally now echoes beyond its borders – for example, if Germany's G-BA decides a new drug has "no added benefit," you can expect insurers in the U.S. to hear about it and perhaps use that in negotiation. Companies need real-time awareness of global HTA outcomes, evolving evidentiary standards, and competitor products' value arguments. Static, point-in-time assessments (like a one-time global value dossier that isn’t updated) are no longer sufficient. A single missed evidence update or an outdated comparator in the model can derail a pricing negotiation worth hundreds of millions. Leading companies have set up “global HTA monitoring” teams that track and disseminate insights from each major HTA review in their disease area — learning from both successes and failures.

Predictive Scenario Modeling

Predictive scenario modeling has become essential for credible submissions. Given the complexity and uncertainty inherent in healthcare, payers themselves conduct sensitivity analyses on models — so manufacturers must do the same preemptively. Robust economic models are now expected to explore multiple scenarios: for instance, best-case, base-case, and worst-case efficacy assumptions; or scenarios with different epidemiological trends. By presenting these in the dossier, companies show they have pressure-tested their drug's value proposition.

Sensitivity analyses that demonstrate the drug remains cost-effective even with conservative inputs can significantly reassure HTA agencies. Moreover, scenario modeling is a strategic tool internally: companies simulate how various pricing schemes or ri arrangements would impact a payer’s budget or a provider’s finances, allowing them to propose innovative contracts that meet payer goals (e.g., budget neutrality) while preserving the drug’s market opportunity.

When policymakers propose drastic measures — like Trump’s demand for 60-90% price cuts — companies with sophisticated models can quickly project the impacts of such cuts on future patient access and even R&D sustainability, strengthening their arguments against blunt price slashes. For example, an internal model might show that a 50% U.S. price cut would force the company to delay or cancel certain pipeline programs, which can be communicated in policy discussions to argue for a more moderate approach.

Internally, scenario models (increasingly enhanced by AI for rapid analysis) help anticipate payer questions. Teams use them to prepare evidence packages for questions like “What if we only reimburse your drug in patients with biomarker X – is it still cost-effective?” or “How does the cost per QALY change if we assume patients only stay on therapy 1 year instead of 3?” Having those answers ready can significantly speed up negotiations and avoid lengthy back-and-forth that delays access.

Embedding this rigor into dossiers ultimately creates more credible and resilient submissions. It demonstrates to payers that the manufacturer has thoroughly evaluated the intervention’s impact from all angles — clinical, economic, uncertainty — and is committed to an evidence-based discussion. This credibility can sometimes expedite positive reimbursement decisions or at least smoother deliberations, because the HTA agency sees the manufacturer as a partner bringing solutions, not a company pushing a high price.

Speed, Precision, and Transparency

Industry leaders are compressing their internal processes dramatically. Tasks that used to take a team of analysts 6 months are being automated with AI-driven literature review and evidence synthesis tools, cutting down preparation time from what might total ~6,000 hours of manual work to well under 100 hours in some cases (according to industry reports). While such figures may be aspirational, the direction is clear: companies are investing in tech and talent to accelerate HTA submissions without sacrificing quality.

Three Critical Competitive Edges

• Speed: Being first to achieve market access can secure millions in revenue and entrenched physician use. The EU's 90-day JCA timeline demands compressed internal processes.

• Precision: Tailoring dossiers exactly to each HTA body's requirements and decision frameworks, eliminating extraneous data and clearly addressing PICO criteria.

• Transparency: Embracing openness by submitting economic models for validation, disclosing assumptions, and acknowledging limitations candidly.

To ensure transparecncy, HTA agencies now often require companies to submit their economic models for validation and to disclose model assumptions, data sources, and any potential conflicts of interest. The new EU HTA regulation explicitly calls for transparency in JCA methodologies to build trust in the shared assessments. Companies that embrace transparency can turn it to their advantage. By inviting external academic review of their models, or by publishing their cost-effectiveness analyses in peer-reviewed journals, they signal confidence in their data. Transparency also involves acknowledging limitations candidly. Rather than trying to obscure a model’s weaknesses, saying “Yes, our model has limitation X; however, we performed these sensitivity analyses and the conclusions didn’t change” can bolster credibility. Payers are more likely to trust a company that shows it’s not hiding anything. And when trust is established, negotiations tend to proceed more smoothly and quickly.

In short, companies that treat HTA excellence as a strategic differentiator — on par with clinical excellence – are finding that they can achieve access in tough markets. They invest in real-time intelligence systems, sophisticated analytical capabilities, and internal processes that prioritize evidence quality and clarity. These investments pay off through faster access and better prices, which in today’s environment can make the difference between a successful launch and a stagnant product.

The Intersection of Trump's Ultimatum with Evolving Value Frameworks

Trump's September 29 ultimatum and the emerging value-based pricing paradigm are on a collision course — one that could reshape the U.S. market. His demand for MFN pricing is essentially an external reference pricing mechanism, importing other countries' price controls into the U.S. system. This runs somewhat against the grain of value-based pricing (VBP), which argues that prices should reflect the clinical and economic value a product delivers in the U.S. healthcare context, not the price concessions a company made in, say, France or Japan.

If companies capitulate to Trump's pressure, they would be voluntarily slashing U.S. prices to match the lowest abroad, perhaps without regard to whether U.S.-specific value evidence might justify a higher price. On the other hand, if they resist, we could see a protracted battle — legal and political — that might drag value assessment further into the spotlight.

Strategic Balancing Act

Market access strategists thus face a tricky balancing act: comply in the short term versus defend long-term pricing based on value. Voluntary compliance (cutting prices) could alleviate immediate political pressure but at the expense of revenue that supports future R&D (an argument companies are making loudly). Fighting back — whether in court or through lobbying — buys time but also risks more drastic measures if the political winds shift decisively toward price controls.

One likely outcome is that companies will try to reframe the discussion around value rather than pure price. We already saw, in responses to Trump's letters, several companies emphasizing their efforts to improve patient access and affordability through value-driven initiatives (such as co-pay support, outcomes-based contracts, or investing in domestic manufacturing to lower costs). The evolving value frameworks (like Medicare’s negotiation criteria, ICER’s influence, etc.) provide a lexicon companies can use: for instance, arguing that “Drug X’s price is high because it prevents strokes and heart attacks, saving the healthcare system $Y — and here’s the evidence.”

It’s worth noting that Trump’s previous attempt to enforce MFN pricing via regulation was struck down by courts for procedural reasons, and the Biden administration chose a different route (direct negotiation via the IRA). This suggests that while the legal challenges to sweeping executive action on drug pricing are substantial, the policy goal of lowering U.S. prices to be more commensurate with other countries enjoys broad support. Thus, even beyond Trump, any future administration — Democrat or Republican — is likely to continue pushing in this direction. The pharmaceutical industry, recognizing this, is moving from outright opposition to proposing alternative solutions (like reforms to the supply chain, value-based agreements, etc.) that could soften the blow.

Emerging Two-Tier System

In Europe, pharma companies have long operated under value frameworks and external reference pricing simultaneously. They have adapted by front-loading value evidence at launch to justify prices to HTA bodies, then negotiating confidential discounts that satisfy payers while maintaining higher list prices that help with reference pricing in other markets. We may see a similar dynamic in the U.S.: companies could offer deeper discounts or rebates to government programs (Medicare, Medicaid) or certain private payers — effectively giving MFN-equivalent prices to those segments — while holding a higher list price for the commercial market.

What is clear is that going forward, any drug launching in the U.S. will face intense scrutiny on value. The days of setting a price based on what the market will bear are ending. Trump’s ultimatum is a symptom of a larger shift: the U.S. is no longer an outlier willing to pay any price. It is converging with other nations that demand proof of value for the money.

Leading Through Value Demonstration in a Transformed Market

Trump's aggressive pricing ultimatum is not a one-off political gambit — it signals a fundamental shift in the ground rules of the U.S. pharmaceutical market. The message to drugmakers is that they must demonstrate their products' worth, or others will dictate their price. At the same time, the maturation of value-based pricing models and HTA processes means the tools and metrics to measure that worth are becoming more standardized and influential.

Strategic Imperatives for Success

For pharmaceutical companies, the implication is clear: they can no longer rely on fragmented, reactive approaches to justify their prices. The old playbook of launching a drug at a high price and then responding to pushback with small discounts or patient assistance programs is increasingly untenable. Instead, success in the coming era requires proactive, integrated strategies that weave together evidence generation, stakeholder engagement, and policy navigation:

Four Pillars of Success

• Embrace Evidence as Core to Pricing: Build a culture where clinical development and commercialization teams work hand in hand from early stages to define the value story and generate supporting evidence. Clinical trials should be designed not only for regulatory approval but also to answer HTA/payer questions. Real-world evidence collection should be planned alongside the marketing strategy, to quickly supplement trial data post-launch. In essence, data is the new currency in pricing negotiations – the more robust and relevant data a company can bring, the stronger its position.

• Treat Policy Changes as Catalysts, Not Threats: Use policies like Medicare negotiation or MFN orders as impetus to innovate rather than simply lobbying against them. For instance, some companies are preemptively offering value-based contracts to payers (refunds if drugs don’t work, etc.) or investing in manufacturing efficiencies and patient selection biomarkers to enhance the value profile of their therapies. By getting ahead of policy shifts, companies can help shape the narrative, be seen as part of the solution, and potentially steer the outcome in their favor.

• Invest in Analytical and AI Capabilities: Build "HTA digital twin" models of healthcare and reimbursement systems to predict global pricing cascades, rapidly iterate submissions, and optimize value demonstration. The complexity of forecasting pricing outcomes under various scenarios (different countries’ actions, competitors, policy changes) is an area where advanced analytics and artificial intelligence such as Loon Waters™ can help.

• Enhance Transparency and Stakeholder Communication: Communicate openly about drug value propositions to build trust and acceptance. In an age of skepticism toward pharma, those companies that communicate openly and credibly about their drug’s value proposition will engender more trust (and likely face less punitive measures). This could translates into publishing outcomes of value-based agreements, collaborating with academic researchers on HTA-related studies, and perhaps even opening up pricing methodologies for public dialogue. When patients, providers, and payers understand why a price is what it is, there could be more acceptance. In contrast, opacity could further breed distrust and heavy-handed regulation.

The industry stands at a crossroads defined by value. Trump's pricing ultimatum and similar global pressures are accelerating a day of reckoning that perhaps was inevitable — a shift from a volume-driven paradigm to a value-driven one. Companies that lead through rapid iteration and value demonstration will not only navigate this storm, but potentially shape the next equilibrium.

The coming years will test the agility and commitment of pharma to uphold its part of the social contract: delivering true innovation at prices commensurate with benefits. Those that succeed in this test – by decisively transforming their approaches – will help ensure a sustainable future where medical breakthroughs continue to reach patients, and do so with broad societal support. In the high-stakes environment created by political demands and value-based expectations, the ability to rapidly generate, validate, and articulate compelling value evidence will separate the leaders from the laggards.. The credibility of the industry, patients’ access to lifesaving therapies, and the future growth of pharma all depend on embracing this new paradigm with decisive action.